PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för bempedoic acid. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

24 hits

Bibliografisk träff 2020-12-01

A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.

Niman S, Rana K, Reid J, Sheikh-Ali M, Lewis T, Choksi RR, Goldfaden RF.

Am J Cardiovasc Drugs · review; journal article · DOI 10.1007/s40256-020-00399-w

Bibliografisk träff 2020-05-01

Bempedoic Acid: First Approval.

Markham A.

Drugs · review; journal article · DOI 10.1007/s40265-020-01308-w

Bibliografisk träff 2020-04-01

Bempedoic acid (Nexletol) for lowering LDL-cholesterol.

Författaruppgift saknas

Med Lett Drugs Ther · journal article

Bibliografisk träff 2020-03-01

Measuring vs Estimating LDL-C Levels in a Clinical Trial of Bempedoic Acid.

Xu HG, Pan S.

JAMA · letter; comment · DOI 10.1001/jama.2020.0488

Bibliografisk träff 2019-11-01

Bempedoic Acid for Lowering LDL Cholesterol.

Honigberg MC, Natarajan P.

JAMA · article-commentary; comment; research support, non-u.s. gov't; editorial; research support, n.i.h., extramural · DOI 10.1001/jama.2019.16598

Bibliografisk träff 2019-11-01

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.

Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB.

JAMA · clinical trial, phase iii; comparative study; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1001/jama.2019.16585

Bibliografisk träff 2019-07-29

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.

Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL.

Eur J Prev Cardiol · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1177/2047487319864671

Bibliografisk träff 2019-05-13

Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.

Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT.

J Clin Lipidol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jacl.2019.05.003

Bibliografisk träff 2019-04-01

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.

Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG.

J Am Heart Assoc · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1161/jaha.118.011662

Bibliografisk träff 2019-04-01

CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins?

Jia X, Virani SS.

J Am Heart Assoc · comment; editorial · DOI 10.1161/jaha.119.012352

Bibliografisk träff 2019-03-01

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.

Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM, CLEAR Harmony Trial.

N Engl J Med · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1056/nejmoa1803917

Bibliografisk träff 2019-02-27

ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.

Ruscica M, Banach M, Sahebkar A, Corsini A, Sirtori CR.

Expert Opin Pharmacother · journal article · DOI 10.1080/14656566.2019.1583209

Bibliografisk träff 2019-02-11

Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials.

Wang X, Luo S, Gan X, He C, Huang R.

Kardiol Pol · meta-analysis; journal article · DOI 10.5603/kp.a2019.0013

Bibliografisk träff 2019-02-01

Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.

Burke AC, Telford DE, Huff MW.

Curr Opin Lipidol · research support, non-u.s. gov't; review; journal article · DOI 10.1097/mol.0000000000000565

Bibliografisk träff 2019-01-01

Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.

Zagelbaum NK, Yandrapalli S, Nabors C, Frishman WH.

Cardiol Rev · review; journal article · DOI 10.1097/crd.0000000000000218

Bibliografisk träff 2018-02-21

Bempedoic Acid (ETC-1002): A Current Review.

Saeed A, Ballantyne CM.

Cardiol Clin · review; journal article · DOI 10.1016/j.ccl.2017.12.007

Bibliografisk träff 2017-01-17

Evaluating bempedoic acid for the treatment of hyperlipidaemia.

Penson P, McGowan M, Banach M.

Expert Opin Investig Drugs · review; journal article · DOI 10.1080/13543784.2017.1280458

Bibliografisk träff 2016-10-01

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.

Bilen O, Ballantyne CM.

Curr Atheroscler Rep · review-article; review; journal article · DOI 10.1007/s11883-016-0611-4

Bibliografisk träff 2016-04-06

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.

Ballantyne CM, McKenney JM, MacDougall DE, Margulies JR, Robinson PL, Hanselman JC, Lalwani ND.

Am J Cardiol · clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.amjcard.2016.03.043

Bibliografisk träff 2016-01-06

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.

Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM.

J Clin Lipidol · clinical trial, phase ii; multicenter study; journal article · DOI 10.1016/j.jacl.2015.12.025

Bibliografisk träff 2015-03-19

Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.

Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS.

J Clin Lipidol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.jacl.2015.03.003

Bibliografisk träff 2014-10-31

ETC-1002: a future option for lipid disorders?

Nikolic D, Mikhailidis DP, Davidson MH, Rizzo M, Banach M.

Atherosclerosis · review; journal article · DOI 10.1016/j.atherosclerosis.2014.10.099

Bibliografisk träff 2013-05-24

ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK.

Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT, Srivastava RAK, Hurley TR, Bradshaw CD, Spahr MA, Newton RS.

J Lipid Res · research-article; journal article · DOI 10.1194/jlr.m035212

Bibliografisk träff 2012-11-01

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.

Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, Houghton JL, Baker C, Naples M, Adeli K, Newton RS.

J Lipid Res · research-article; journal article · DOI 10.1194/jlr.m030528